Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Allurion Technologies, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Allurion Technologies, Inc.

Regulatory records
3
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 3 FDA records to the applicant name Allurion Technologies, Inc.. It includes 1 original PMA approval. 2 entries are PMA supplements. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Feb 20, 2026 to Sep 23, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code LTI appears in 3 of the 3 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P250023, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 11 Huron Dr., Natick, MA, 01760. Recorded on P250023/S002, decision dated Sep 23, 2026.

Changes described in PMA records

P250023/S002: Allurion Gastric Balloon System

The FDA database entry records an approval decision, dated 2026-09-23, for supplement P250023/S002 to PMA P250023, the Allurion Gastric Balloon System. The supplement type is the Normal 180 Day Track No User Fee, and the stated reason is a postapproval study protocol. The applicant is Allurion Technologies, Inc. The device falls under product code LTI in the category implant, intragastric for morbid obesity, within Gastroenterology, Urology.

The source statement identifies the changed item as the revised protocol for the post-approval study Allurion Gastric Balloon PAS. The announcement of the revised protocol does not by itself establish safety or clinical effectiveness of the device. The entry does not describe protocol content, study endpoints, patient numbers, or trial results; those details are absent from the supplied fields. It does not grant a new approval of the whole system.

FDA approval-order wording

the revised protocol for the post-approval study (PAS) Allurion Gastric Balloon PAS

Sep 23, 2026 · Normal 180 Day Track No User Fee

P250023/S001: Allurion Gastric Balloon System

FDA’s recorded scope: revisions to the patient labeling, physician labeling and patient information card to enhance product safety information

Sep 9, 2026 · Special (Immediate Track)

P250023: Allurion Gastric Balloon System

The FDA database record P250023 shows an approval decision dated 2026-02-20 for the Allurion Gastric Balloon System (AGBS), submitted by Allurion Technologies, Inc. under product code LTI, device category "IMPLANT, INTRAGASTRIC FOR MORBID OBESITY." The record lists no supplement type or supplement reason, so the fields supplied do not identify a prior PMA or establish any change from an earlier cleared scope; the decision is described only as an approval.

Per the source statement, the approved indication covers short-term limited weight loss in adults aged 22 to 65 years with BMI from 30 to 40 kg/m2 who have had at least one unsuccessful weight loss program attempt. The system is to be used with a moderate intensity lifestyle modification therapy program, consists of up to two Allurion Balloons placed during a 10-month period, and has a variable residence time averaging 15.3 weeks. This is the applicant's stated purpose, not independent evidence of safety or clinical effectiveness.

FDA approval-order wording

Approval for the Allurion Gastric Balloon System (AGBS) is indicated to promote short-term limited weight loss in adult individuals with obesity between the ages of 22 years and 65 years with a body mass index (BMI) greater than or equal to 30 kg/m2 and less than or equal to 40 kg/m2 who have had at least one unsuccessful attempt at a weight loss program. The residence time for each AGBS is variable with an average observed residence time of 15.3 weeks. The AGBS is to be used in conjunction with a moderate intensity lifestyle modification therapy program. The AGBS consists of up to two Allurion Balloons placed during a 10-month period.

Feb 20, 2026

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Allurion Technologies, Inc.PMA supplementSep 23, 2026FDA
Allurion Technologies, Inc.PMA supplementSep 9, 2026FDA
Allurion Technologies, Inc.PMA approvalFeb 20, 2026FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 20, 2026.